These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
110 related articles for article (PubMed ID: 78296)
1. Immunogenicity and antigenicity of soluble cross-linked enzyme/albumin polymers: Advantages for enzyme therapy. Remy MH; Poznansky MJ Lancet; 1978 Jul; 2(8080):68-70. PubMed ID: 78296 [TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo activity of soluble cross-linked uricase-albumin polymers: a model for enzyme therapy. Poznansky MJ Life Sci; 1979 Jan; 24(2):153-8. PubMed ID: 763074 [No Abstract] [Full Text] [Related]
3. Studies on antigenicity of the polyethylene glycol (PEG)-modified uricase. Tsuji J; Hirose K; Kasahara E; Naitoh M; Yamamoto I Int J Immunopharmacol; 1985; 7(5):725-30. PubMed ID: 2412977 [TBL] [Abstract][Full Text] [Related]
4. Comparative immunology of mammalian uricase using anti-hog liver uricase. Htay HH; Sato K; Tamaki K; Tsutsumi H; Katsumata Y Comp Biochem Physiol B; 1989; 92(3):583-6. PubMed ID: 2495886 [TBL] [Abstract][Full Text] [Related]
5. A Therapeutic Uricase with Reduced Immunogenicity Risk and Improved Development Properties. Nyborg AC; Ward C; Zacco A; Chacko B; Grinberg L; Geoghegan JC; Bean R; Wendeler M; Bartnik F; O'Connor E; Gruia F; Iyer V; Feng H; Roy V; Berge M; Miner JN; Wilson DM; Zhou D; Nicholson S; Wilker C; Wu CY; Wilson S; Jermutus L; Wu H; Owen DA; Osbourn J; Coats S; Baca M PLoS One; 2016; 11(12):e0167935. PubMed ID: 28002433 [TBL] [Abstract][Full Text] [Related]
6. A possible role for glass bead immobilized enzymes as therapeutic agents (immobilized uricase as enzyme therapy for hyperuricemia). Venter JC; Venter BR; Dixon JE; Kaplan NO Biochem Med; 1975 Jan; 12(1):79-91. PubMed ID: 806289 [No Abstract] [Full Text] [Related]
7. Induction of tolerance in mice by uricase and monomethoxypolyethylene glycol-modified uricase. Savoca KV; Davis FF; Palczuk NC Int Arch Allergy Appl Immunol; 1984; 75(1):58-67. PubMed ID: 6746105 [TBL] [Abstract][Full Text] [Related]
8. Immunological studies on modified enzymes. I. soluble L-asparaginase/mouse albumin copolymer with enzyme activity and substantial loss of immunogenicity. Yagura T; Kamisaki Y; Wada H; Yamamura Y Int Arch Allergy Appl Immunol; 1981; 64(1):11-8. PubMed ID: 7450899 [TBL] [Abstract][Full Text] [Related]
9. Immunogenicity of glutaraldehyde treated homologous monomeric albumin in rabbits. Onica D; Dobre MA; Lenkei R Immunochemistry; 1978 Dec; 15(12):941-4. PubMed ID: 86498 [No Abstract] [Full Text] [Related]
10. Immunological properties of uricase conjugated to neutral soluble polymers. Caliceti P; Schiavon O; Veronese FM Bioconjug Chem; 2001; 12(4):515-22. PubMed ID: 11459455 [TBL] [Abstract][Full Text] [Related]
11. Modification of yeast uricase with polyethylene glycol: disappearance of binding ability towards anti-uricase serum. Nishimura H; Ashihara Y; Matsushima A; Inada Y Enzyme; 1979; 24(4):261-4. PubMed ID: 573687 [TBL] [Abstract][Full Text] [Related]
12. Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase. Ganson NJ; Kelly SJ; Scarlett E; Sundy JS; Hershfield MS Arthritis Res Ther; 2006; 8(1):R12. PubMed ID: 16356199 [TBL] [Abstract][Full Text] [Related]
13. A comparison of the anti-idiotypic responses generated by antibodies to a protein and a hapten: a common interspecies idiotype on antibodies against human albumin induces an idiotypic network in rabbits. Comacchio RM; Bradley J; Hohmann AW Immunol Cell Biol; 1996 Feb; 74(1):72-80. PubMed ID: 8934657 [TBL] [Abstract][Full Text] [Related]
14. [Experimental study of the immune response to swine liver urate oxidase]. Levi EV; Kashkin AP; Putilova NE; Cherniavskaia MA; Surina TIa Zh Mikrobiol Epidemiol Immunobiol; 1978 Aug; (8):129-34. PubMed ID: 742273 [TBL] [Abstract][Full Text] [Related]
15. Enhanced anti-inflammatory effect and reduced immunogenicity of bovine liver superoxide dismutase by conjugation with homologous albumin. Wong K; Cleland LG; Poznansky MJ Agents Actions; 1980 Jun; 10(3):231-9. PubMed ID: 7405750 [TBL] [Abstract][Full Text] [Related]
16. Designing and engineering of a site-specific incorporation of a keto group in uricase. Fang Z; Liu Y; Liu J; Sun R; Chen H; Gao X; Yao W Chem Biol Drug Des; 2011 Sep; 78(3):353-60. PubMed ID: 21585711 [TBL] [Abstract][Full Text] [Related]
17. Use of the uricase-inhibited rat as an animal model in toxicology. Stavric B; Nera EA Clin Toxicol; 1978; 13(1):47-74. PubMed ID: 367691 [TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout. Sundy JS; Ganson NJ; Kelly SJ; Scarlett EL; Rehrig CD; Huang W; Hershfield MS Arthritis Rheum; 2007 Mar; 56(3):1021-8. PubMed ID: 17328081 [TBL] [Abstract][Full Text] [Related]
19. Reduction of plasma urate levels in the cockerel with polyethylene glycol-uricase. Abuchowski A; Karp D; Davis FF J Pharmacol Exp Ther; 1981 Nov; 219(2):352-4. PubMed ID: 7288624 [TBL] [Abstract][Full Text] [Related]
20. Improved modification of yeast uricase with polyethylene glycol, accompanied with nonimmunoreactivity towards anti-uricase serum and high enzymic activity. Nishimura H; Matsushima A; Inada Y Enzyme; 1981; 26(1):49-53. PubMed ID: 7194181 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]